The rising prevalence of neurological diseases may possibly be attributed to western lifestyle factors.
Whilst Monepantel can have a potential therapeutic benefit by reducing toxic protein build up, it would be an advantage to have a healthier baseline population in the first place. I'm a strong believer that the typical western diet and attitude to physical activity may have a part to play in reversing the increase in neurological diseases.
I would love to have a conversation with Dr's Mathers & Rowe to ask if they recommend dietary changes to MND patients upon presentation to their clinics. It would be interesting to see if any natural anti-inflammatory supplement such as turmeric could work in conjunction with Monepantel to enhance positive outcomes.
The cause of MND is unknown, and I am not for a moment suggesting our trial patients are suffering their conditions due to lifestyle. My only observation is that a holistic approach to treatment which includes Monepantel could be beneficial.
I agree that the ever increasing Alzheimer's market size presents a huge opportunity for PAA.
But on the flip side, it's sad that so many people will ultimately develop this disease.
Good health to all....Cheers, Thrifty
- Forums
- ASX - By Stock
- PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
The rising prevalence of neurological diseases may possibly be...
-
-
- There are more pages in this discussion • 620 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.22M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.5¢ | $244.3K | 1.244M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 257206 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.195 |
15 | 925498 | 0.190 |
11 | 271447 | 0.185 |
17 | 418587 | 0.180 |
3 | 259030 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 257206 | 7 |
0.205 | 247264 | 3 |
0.210 | 193616 | 5 |
0.215 | 353018 | 4 |
0.220 | 479713 | 7 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online